In Re: Zetia (Ezetimibe) Antitrust Litigation

Track this case

Case Number:

2:18-md-02836

Court:

Virginia Eastern

Nature of Suit:

Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Rebecca Beach Smith

Firms

Companies

Sectors & Industries:

February 13, 2023
Merck, Glenmark Must Face Zetia Antitrust MDL At April Trial

A Virginia federal judge has upheld a magistrate judge's recommendation to deny Merck and Glenmark's bids to end antitrust multidistrict litigation accusing the drugmakers of conspiring to delay generic competition for the branded cholesterol medication Zetia, teeing up the case for an April jury trial.
September 07, 2022
Merck, Glenmark Antitrust MDL Must Go To Jury, Judge Says

A Virginia magistrate judge has recommended denying Merck and Glenmark's bids to end antitrust multidistrict litigation accusing the drugmakers of conspiring to delay generic competition for the branded cholesterol medication Zetia, finding there are numerous material factual disputes that should go to a jury.
August 16, 2022
Merck's Zetia Arguments Don't Misuse Privilege, Judge Says

A Virginia federal judge will allow Merck to make certain arguments about how its executives interpreted a patent litigation settlement with rival drugmaker Glenmark over cholesterol drug Zetia despite claims from antitrust plaintiffs that the company previously made the information off-limits by claiming it's privileged attorney-client communication.
June 27, 2022
Humana Wants To Add Federal Antitrust Claims To Zetia Case

Humana Inc. asked a Virginia federal court for permission to add claims under federal antitrust law to its case accusing Merck and Glenmark of scheming to delay generic forms of the cholesterol drug Zetia.
April 14, 2022
Zetia Wholesalers Denied Class Cert. In Generics-Delay Suit

A group of wholesalers accusing Merck and Glenmark Pharmaceuticals of a scheme to delay a generic cholesterol drug are unlikely to force a settlement on the companies after a Virginia federal judge refused to certify a proposed class to pursue the claims.
February 25, 2022
Zetia Buyers Get Narrow Market In Generic-Delay Suit

A Virginia federal court has sided with buyers in their bid to limit the scope of competition considered in their suit accusing Merck and Glenmark of striking a deal to keep generic versions of cholesterol drug Zetia off the market.
February 09, 2022
Zetia Buyers Defend Class Cert. As 'Common Business Sense'

Direct buyers of cholesterol drug Zetia urged a Virginia federal court Tuesday to reject a recommendation against class certification in multidistrict litigation accusing Merck and Glenmark of scheming to delay generic versions, arguing that presumptions of dozens of wholesalers joining without certification ignores business realities.
January 25, 2022
Zetia Buyers Should Be Denied Class Cert., Court Told

A Virginia federal judge has said dozens of direct buyers of cholesterol drug Zetia should not receive class certification in multidistrict litigation against Merck and Glenmark over a purported scheme to delay a generic version of the product.
November 16, 2021
Merck, Glenmark Want Jury To Decide Zetia Antitrust Market

Merck and Glenmark are not happy about a Virginia federal magistrate's recommendation that a suit accusing the pharmaceutical companies of hatching an anti-competitive plan to keep a cholesterol drug off the market should focus on a narrower market.
November 02, 2021
Buyers Win Backing For Narrow Market In Zetia Generic Suit

A suit accusing Merck and Glenmark of striking an anti-competitive deal to keep a cheaper version of Zetia at bay should focus on only the alleged harm to buyers of the blockbuster cholesterol drug and its generics, a Virginia federal magistrate has found.